Genzyme anticipates a shortage in the US beginning in mid-April and extending through mid-June.
According to the European Medicines Agency Genzyme will only be able to reach around 45% of the total EU demand.
The company is notifying health care providers of the supply interruption so that they may schedule individual patient treatments appropriately during this time.
Genzyme said it is working hard to get regulatory approval for transferring its fill/finish to a third party contract manufacturing facility.
Thyrogen is indicated for the diagnosis and treatment of thyroid tissue remnants post thyroidectomy in patients with thyroid cancer.